A Global Phase II Trial Puts Peptide Immunotherapy in the Spotlight

A Certificate of Analysis (COA) is the single most important document that comes with a research peptide order, yet it's also one of the most overlooked. Knowing how to read one — and what to look for — turns an unfamiliar lab report into a clear signal of quality and identity. Here's a practical breakdown of what every COA should tell you.

Reconstituting a lyophilized peptide correctly is one of the most important steps in any research protocol. Use too much or too little bacteriostatic water, and your concentration math (and your results) can be thrown off before you even start. Here's a clear walkthrough of the process our research team follows.

Relocating for a conference, shipping samples between labs, or just moving vials from the freezer to the bench: every step outside cold storage puts peptide integrity at risk. Here's what our research team looks at when planning safe transport for temperature-sensitive compounds.

This week's reporting on compounded GLP-1 products raises a question that goes beyond weight-loss injections: how do you know a compounded peptide is chemically what it claims to be? Stanford Medicine clinicians and independent lab analyses are documenting real gaps — unapproved salt forms, undisclosed additives, and even newly formed molecules that don't exist in the approved drug. Here's what the research actually found, and why verified sourcing is the real answer.

While everyone's been focused on which peptides made this week's FDA advisory vote, a quieter story has been unfolding alongside it: the agency's own scientists recommended against every peptide under review, and now patient safety groups are formally warning that the panel's decision came without the evidence needed to justify it. Here's what ECRI, ISMP, and the Partnership for Safe Medicines actually said, and what it means for anyone buying peptides today.

While everyone's been watching the FDA's advisory committee vote, a new Washington Post investigation points to a bigger, quieter risk: the medspas and wellness clinics actually injecting peptides into consumers face less regulatory oversight than your neighborhood restaurant. Here's what the investigation found, why the gap exists, and what it means for anyone buying peptides today.

For months, social media has insisted that Robert F. Kennedy Jr. already "legalized" a wave of popular research peptides. This week's FDA advisory committee vote added fuel to that story, but the actual paper trail tells a more complicated tale. Here's what's really changed, what's still just talk, and what it means if you're buying peptides today.

This week's FDA Pharmacy Compounding Advisory Committee meeting ended with six peptides recommended for the agency's 503A Bulk Drug Substances List and one turned away. The vote made headlines, but the fine print matters more than the tally. Here is what the committee actually decided, what it does not decide, and why sourcing still matters no matter how the FDA rules.

An FDA advisory panel's split vote on peptide compounding sent Hims & Hers Health shares swinging Thursday, as Wall Street analysts weighed a potential multi-billion dollar telehealth opportunity against lingering safety concerns raised by the agency's own scientists.